CEO Michael Carrel emphasized that 2024 was a year of "continued growth," highlighted by achieving $465 million in revenue, representing a 17% increase. Key drivers included robust performances in ...

In a report released yesterday, Geulah Livshits from Chardan Capital maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research ...

For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...

The headline numbers for Antero Midstream (AM) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall ...

Sees overall market size of 50M-55M tests with greater than 50% of flu revenue coming from flu/COVID-19 combo test; Full year 2025 COVID-19 ...

As global markets navigate the complexities of tariff uncertainties and mixed economic signals, investors are increasingly focused on strategies that provide stability and income. In such a climate, ...

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to ...

TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...